Supernus Pharma (SUPN) Tops Q3 EPS by 17c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.40, $0.17 better than the analyst estimate of $0.23. Revenue for the quarter came in at $148.5 million versus the consensus estimate of $142.12 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance